Difference between VAPP and VDPV in polio vaccine.
Reading File
Finding Sources
Finding Sources
Searching the Web
VAPP vs VDPV difference polio vaccine comparison
Reading File
Reading File
I now have comprehensive information from Park's textbook, Red Book 2021, and WHO sources. Let me compile the full answer.
VAPP vs VDPV: Key Differences
Both are rare complications of the Oral Polio Vaccine (OPV), which contains live attenuated Sabin strains. The distinction lies in the mechanism, scale of risk, genetic definition, and epidemiological behavior.
VAPP - Vaccine-Associated Paralytic Poliomyelitis
| Feature | Details |
|---|---|
| Definition | Paralytic polio occurring in an OPV recipient or their close contact, caused by OPV virus reverting to neurovirulence during replication in the gut |
| Mechanism | Early genetic mutations occur in the attenuated OPV strain during replication in the intestine, reverting it to a neurovirulent form - this is a normal but rare event |
| Timing | 7-60 days after OPV dose, with neurological deficit persisting at 60 days |
| Who is at risk | (a) Recipient VAPP (rVAPP): the vaccinated child, especially on the first dose; (b) Contact VAPP (cVAPP): unimmunized close contacts (family members, caregivers) |
| Incidence | ~1 case per 2.4-2.7 million OPV doses; ~4 cases per million birth cohort/year (Park's, p. 5659-5660); WHO estimates 2-4 cases per million birth cohort |
| Most frequent serotype | Sabin type 3 (60% of VAPP cases), then type 2, then type 1 |
| Highest risk group | First-dose recipients; patients with primary B-lymphocyte immunodeficiencies (greatly increased risk) |
| Spread | NO person-to-person transmission; VAPP does not spread to cause additional paralysis cases - risk is strictly to the individual and immediate contacts |
| Outbreaks | No outbreaks associated with VAPP |
| Genetic change | Minimal - early reversion mutations, does not meet VDPV threshold |
VDPV - Vaccine-Derived Poliovirus
| Feature | Details |
|---|---|
| Definition | OPV-derived poliovirus strains that have undergone prolonged replication and accumulated genetic changes, now biologically resembling wild poliovirus (WPV) |
| Genetic threshold | Differ from parental Sabin strains by >1% of VP1 nucleotides for types 1 and 3; >0.6% for type 2 (consistent with replication >4-6 weeks, which is much longer than normal OPV replication) (Park's, p. 5665-5672) |
| Mechanism | Prolonged replication (either in the gut of an immunocompromised host or through sustained person-to-person transmission in under-immunized communities) allows accumulation of mutations that restore neurovirulence AND transmissibility |
| Diagnosis | Real-time RT-PCR (rRT-PCR) targeting nucleotide substitutions that occur early in VDPV emergence |
Three Categories of VDPV (Park's p. 5677-5696):
- cVDPV (Circulating VDPV) - Evidence of person-to-person transmission in the community; occurs in areas of low vaccination coverage; can cause outbreaks indistinguishable from WPV; most cases are type 2
- iVDPV (Immunodeficiency-associated VDPV) - Found in persons with primary B-lymphocyte immunodeficiencies who shed the virus for months-years; may excrete the virus long after vaccination without developing paralysis, posing a community risk
- aVDPV (Ambiguous VDPV) - Cannot be classified as cVDPV or iVDPV; may represent undetected chains of transmission or isolated excretion from an unknown immunocompromised individual
Head-to-Head Comparison Table
| Feature | VAPP | VDPV |
|---|---|---|
| Nature | Individual adverse event | Viral evolution phenomenon |
| Genetic divergence | Minimal (early reversion) | >1% VP1 nucleotides from Sabin strain |
| Replication period | Normal (4-6 weeks) | Prolonged (weeks to years) |
| Transmission | No community spread; isolated to recipient/close contacts | Can spread person-to-person (cVDPV); potential for outbreaks |
| Outbreak potential | None | Yes (cVDPV causes WPV-like outbreaks) |
| Scale of risk | Individual | Community/population |
| Most common setting | Any OPV-using country | Areas with low immunization coverage |
| Resemblance to WPV | No | Yes (biologically similar to WPV) |
| Immunocompromised risk | Higher risk for VAPP | Drives iVDPV - prolonged shedding for years |
| Most common serotype | Type 3 (60%) | Type 2 (>90% of cVDPV outbreaks) |
| Prevention | Switch to IPV | Maintain high OPV coverage (>90%) until OPV is withdrawn; use IPV |
Key Clinical Points
- Both are clinically indistinguishable from wild poliovirus paralysis; differentiation requires laboratory analysis (Park's, p. 5657-5658)
- VAPP is an individual-level risk; VDPV is a community-level risk
- More global cases of paralytic disease are now caused by vaccine-related viruses (VAPP and cVDPV) combined than by wild poliovirus, making this distinction epidemiologically important (Red Book 2021, p. 934-935)
- The global switch from trivalent OPV to bivalent OPV in April 2016 was driven by the fact that type 2 OPV caused >90% of cVDPV outbreaks
- A novel type 2 OPV (nOPV2) with substantially lower risk of neurovirulence reversion has been approved for use to control type 2 cVDPV outbreaks (Goldman-Cecil Medicine)
- Switching to IPV eliminates both VAPP and VDPV risk entirely, as IPV contains no live virus
Sources: Park's Textbook of Preventive and Social Medicine (pp. 5654-5696); Red Book 2021 Report of the Committee on Infectious Diseases (pp. 934-935); WHO Fact Sheet on VAPP and cVDPV; Harrison's Principles of Internal Medicine 22E.
This is a shared conversation. Sign in to Orris to start your own chat.